Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 599 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tumors Metastatic to Brain Clear all
Active, not recruiting Not applicable Interventional

A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

NCT05341739
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Pre-operative Stereotactic Radiosurgery
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

NCT00837928
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bendamustine, laboratory biomarker analysis, Surgical Resection of Brain Metastases, Stereotactic body radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
John Grecula
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

NCT00002708
View directory record Official record
Conditions
Metastatic Cancer
Interventions
surgical procedure, radiation therapy, stereotactic radiosurgery
Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
240
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

NCT06764940
View directory record Official record
Conditions
HER2-negative Breast Cancer Patients With Brain Metastases
Interventions
Utidelone, Utidelone in combination with capecitabine
Drug
Lead sponsor
Biostar Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

NCT02598427
View directory record Official record
Conditions
HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Kimberly Blackwell
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

NCT03741673
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed No phase listed Observational

Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases

NCT01445483
View directory record Official record
Conditions
Brain Metastasis, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

NCT03696030
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
Interventions
Chimeric Antigen Receptor T-Cell Therapy
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases

NCT00582075
View directory record Official record
Conditions
Cancer, Brain Metastases
Interventions
temozolomide
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 15, 2026, 5:32 AM EDT
Withdrawn No phase listed Observational

FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions

NCT02328300
View directory record Official record
Conditions
Brain Lesions, Brain Metastasis, Brain Metastases
Interventions
FLT PET/MR
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

NCT04283994
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

NCT03436433
View directory record Official record
Conditions
Glioma, Glioma of Brain, Brain Tumor
Interventions
Lacosamide, Levetiracetam
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 4 Interventional

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

NCT03016741
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Early Phase 1 Interventional

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

NCT03930173
View directory record Official record
Conditions
Secondary Malignant Neoplasm of Brain and Cerebral Meninges
Interventions
18F-fluciclovine, PET/CT of the brain
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 15, 2026, 5:32 AM EDT
Not listed Phase 1Phase 2 Interventional

Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

NCT00787982
View directory record Official record
Conditions
Brain Neoplasms
Interventions
MRI-Guided Laser Induced Thermal Therapy
Device
Lead sponsor
Visualase, Inc.
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Oct 15, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional

Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma

NCT03406273
View directory record Official record
Conditions
Relapsed Neuroblastoma
Interventions
Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS)
Radiation
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

NCT00003563
View directory record Official record
Conditions
Metastatic Cancer
Interventions
WBRT, MGd
Radiation · Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
31
States / cities
Greenbrae, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

NCT00541138
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

NCT00617539
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 15, 2026, 5:32 AM EDT